Literature DB >> 11929339

Pharmacological approaches for the treatment of obesity.

José-Antonio Fernández-López1, Xavier Remesar, Màrius Foz, Marià Alemany.   

Abstract

The high incidence of obesity, its multifactorial nature, the complexity and lack of knowledge of the bodyweight control system, and the scarcity of adequate therapeutics have fuelled anti-obesity drug development during a considerable number of years. Irrespective of the efforts invested by researchers and companies, few products have reached a minimum level of effectiveness, and even fewer are available in medical practice. As a consequence of anti-obesity research, our knowledge of the bodyweight control system increased but, despite this, the pharmacological approaches to the treatment of obesity have not resulted yet in effective drugs. This review provides a panoramic of the multiple different approaches developed to obtain workable drugs. These approaches, however, rely in only four main lines of action: control of energy intake, mainly through modification of appetite;control of energy expenditure, essentially through the increase of thermogenesis;control of the availability of substrates to cells and tissues through hormonal and other metabolic factors controlling the fate of the available energy substrates; andcontrol of fat reserves through modulation of lipogenesis and lipolysis in white adipose tissue. A large proportion of current research is centred on neuropeptidic control of appetite, followed by the development of drugs controlling thermogenic mechanisms and analysis of the factors controlling adipocyte growth and fat storage. The adipocyte is also a fundamental source of metabolic signals, signals that can be intercepted, modulated and used to force the brain to adjust the mass of fat with the physiological means available. The large variety of different approaches used in the search for effective anti-obesity drugs show both the deep involvement of researchers on this field and the large amount of resources devoted to this problem by pharmaceutical companies. Future trends in anti-obesity drug research follow closely the approaches outlined; however, the increasing mass of information on the molecular basis of bodyweight control and obesity will in the end prevail in our search for effective and harmless anti-obesity drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929339     DOI: 10.2165/00003495-200262060-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  464 in total

Review 1.  A review of the physiological bases of the anorexic action of phenylpropanolamine (d,1-norephedrine).

Authors:  P J Wellman
Journal:  Neurosci Biobehav Rev       Date:  1990       Impact factor: 8.989

2.  Changes in weight during a 1-year trial of fluoxetine.

Authors:  D Michelson; J D Amsterdam; F M Quitkin; F W Reimherr; J F Rosenbaum; J Zajecka; K L Sundell; Y Kim; C M Beasley
Journal:  Am J Psychiatry       Date:  1999-08       Impact factor: 18.112

Review 3.  Effect of sucrose and sweeteners on appetite and energy intake.

Authors:  J E Blundell; S M Green
Journal:  Int J Obes Relat Metab Disord       Date:  1996-03

4.  5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.

Authors:  J R Martin; M Bös; F Jenck; J Moreau; V Mutel; A J Sleight; J Wichmann; J S Andrews; H H Berendsen; C L Broekkamp; G S Ruigt; C Köhler; A M Delft
Journal:  J Pharmacol Exp Ther       Date:  1998-08       Impact factor: 4.030

5.  Effects of ZD7114, a selective beta3-adrenoceptor agonist, on neuroendocrine mechanisms controlling energy balance.

Authors:  E Savontaus; U Pesonen; J Rouru; R Huupponen; M Koulu
Journal:  Eur J Pharmacol       Date:  1998-04-24       Impact factor: 4.432

6.  Effects of growth hormone treatment on the leptin system and on energy expenditure in abdominally obese men.

Authors:  C Karlsson; K Stenlöf; G Johannsson; P Mårin; P Björntorp; B A Bengtsson; B Carlsson; L M Carlsson; L Sjöström
Journal:  Eur J Endocrinol       Date:  1998-04       Impact factor: 6.664

7.  The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women.

Authors:  A Astrup; B Buemann; N J Christensen; S Toubro; G Thorbek; O J Victor; F Quaade
Journal:  Metabolism       Date:  1992-07       Impact factor: 8.694

8.  Lack of effect of dehydroepiandrosterone in obese men.

Authors:  K S Usiskin; S Butterworth; J N Clore; Y Arad; H N Ginsberg; W G Blackard; J E Nestler
Journal:  Int J Obes       Date:  1990-05

9.  Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.

Authors:  J R Arch; A T Ainsworth; R D Ellis; V Piercy; V E Thody; P L Thurlby; C Wilson; S Wilson; P Young
Journal:  Int J Obes       Date:  1984

10.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

View more
  7 in total

Review 1.  Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Authors:  Trino Baptista; N M K Ng Ying Kin; Serge Beaulieu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Understanding the comparative molecular field analysis (CoMFA) in terms of molecular quantum similarity and DFT-based reactivity descriptors.

Authors:  Alejandro Morales-Bayuelo; Ricardo A Matute; Julio Caballero
Journal:  J Mol Model       Date:  2015-05-28       Impact factor: 1.810

3.  Comparative effects of oleoyl-estrone and a specific beta3-adrenergic agonist (CL316, 243) on the expression of genes involved in energy metabolism of rat white adipose tissue.

Authors:  Raquel Ferrer-Lorente; Cristina Cabot; José-Antonio Fernández-López; Marià Alemany
Journal:  Nutr Metab (Lond)       Date:  2010-02-25       Impact factor: 4.169

Review 4.  Current management strategies for coexisting diabetes mellitus and obesity.

Authors:  Andre J Scheen
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  A review of the effects of Capsicum annuum L. and its constituent, capsaicin, in metabolic syndrome.

Authors:  Setareh Sanati; Bibi Marjan Razavi; Hossein Hosseinzadeh
Journal:  Iran J Basic Med Sci       Date:  2018-05       Impact factor: 2.699

6.  Leucine deprivation decreases fat mass by stimulation of lipolysis in white adipose tissue and upregulation of uncoupling protein 1 (UCP1) in brown adipose tissue.

Authors:  Ying Cheng; Qingshu Meng; Chunxia Wang; Houkai Li; Zhiying Huang; Shanghai Chen; Fei Xiao; Feifan Guo
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

7.  Sympathomimetic activity of a Hoodia gordonii product: a possible mechanism of cardiovascular side effects.

Authors:  Orsolya Roza; Norbert Lovász; István Zupkó; Judit Hohmann; Dezső Csupor
Journal:  Biomed Res Int       Date:  2013-11-06       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.